{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T23:57:03Z","timestamp":1794873423911,"version":"4.9.1"},"reference-count":50,"publisher":"Oxford University Press (OUP)","issue":"12","license":[{"start":{"date-parts":[[2025,7,12]],"date-time":"2025-07-12T00:00:00Z","timestamp":1752278400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,12,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To describe the outcomes of pregnancies exposed to IL-1 targeted therapies (anti-IL-1): anakinra and\/or canakinumab.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We performed a descriptive observational study based on data from CRAT, the French Teratology Information Service. We included prospective and retrospective pregnancies exposed to anakinra and\/or canakinumab with known outcomes. Pregnancy, foetal and neonatal outcomes were analysed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Between 2007 and 2023, 57 pregnant women exposed to anti-IL-1 were referred, including 27 (47.3%) treated for Still\u2019s disease. Among prospective cases, 52 foetuses (one twin pregnancy) were exposed to anakinra (n\u2009=\u200943), canakinumab (n\u2009=\u20095) or both medications (n\u2009=\u20094). For anakinra: (i) 40\/47 cases (85.1%) were exposed during the first trimester (T1), and 21\/47 (44.7%) during all pregnancy, (ii) 40\/47 (85.1%) resulted in livebirths, 5\/47 (10.6%) early miscarriages, one medical abortion (mother-transmitted syndrome) and one elective abortion, (iii) one isolated hypospadias was reported (anakinra between 0 and 4\u2009weeks of gestation), for a prevalence of major congenital malformation of 3.03% IC 95% [0.1\u201315.1] among T1-exposed pregnancies. For canakinumab, all cases (9\/9) were exposed during T1 and 2\/9 during all pregnancy: all resulted in livebirths with no malformation. Concerning retrospective pregnancies (anakinra\u2009=\u20096\/6), all resulted in live births. Cardiopathy with hypospadias was identified in a child with a rare genetic anomaly. No significant effects were reported while breastfeeding (n\u2009=\u20099).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In this study, the largest series to date, our results do not suggest occurrence of specific negative outcomes in pregnancies exposed to anti-IL-1. The imputability of anakinra in the malformations observed is unlikely. If needed, their use during pregnancy should be considered.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/rheumatology\/keaf387","type":"journal-article","created":{"date-parts":[[2025,7,12]],"date-time":"2025-07-12T16:46:52Z","timestamp":1752338812000},"page":"6106-6113","source":"Crossref","is-referenced-by-count":7,"title":["Exposure during pregnancy to Il-1 targeted therapies and pregnancy, foetal and neonatal outcomes: a study from the French Teratology Information Service"],"prefix":"10.1093","volume":"64","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7510-9364","authenticated-orcid":false,"given":"Valentine","family":"Faure-Bardon","sequence":"first","affiliation":[{"name":"Department of Gynecology and Obstetrics, Piti\u00e9-Salp\u00eatri\u00e8re Hospital, Sorbonne University, AP-HP , Paris,","place":["France"]},{"name":"URP 7328 Federation for Research into Innovative Explorations and Therapeutics in Utero, Paris-Cit\u00e9 University , Paris,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delphine","family":"Beghin","sequence":"additional","affiliation":[{"name":"AP-HP, Sorbonne Universit\u00e9, H\u00f4pital Piti\u00e9-Salp\u00eatri\u00e8re, D\u00e9partement de Sant\u00e9 Publique, Centre de R\u00e9f\u00e9rence sur les Agents T\u00e9ratog\u00e8nes (CRAT) , Paris,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Fautrel","sequence":"additional","affiliation":[{"name":"Sorbonne Universit\u00e9 \u2013 Assistance Publique H\u00f4pitaux de Paris, INSERM UMRS 1136 PEPITES team, Department of Rheumatology, Piti\u00e9 Salp\u00eatri\u00e8re Hospital , Paris,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathilde","family":"Latour","sequence":"additional","affiliation":[{"name":"AP-HP, Sorbonne Universit\u00e9, H\u00f4pital Piti\u00e9-Salp\u00eatri\u00e8re, D\u00e9partement de Sant\u00e9 Publique, Centre de R\u00e9f\u00e9rence sur les Agents T\u00e9ratog\u00e8nes (CRAT) , Paris,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Vauzelle","sequence":"additional","affiliation":[{"name":"AP-HP, Sorbonne Universit\u00e9, H\u00f4pital Piti\u00e9-Salp\u00eatri\u00e8re, D\u00e9partement de Sant\u00e9 Publique, Centre de R\u00e9f\u00e9rence sur les Agents T\u00e9ratog\u00e8nes (CRAT) , Paris,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camille","family":"Reinaud","sequence":"additional","affiliation":[{"name":"AP-HP, Sorbonne Universit\u00e9, H\u00f4pital Piti\u00e9-Salp\u00eatri\u00e8re, D\u00e9partement de Sant\u00e9 Publique, Centre de R\u00e9f\u00e9rence sur les Agents T\u00e9ratog\u00e8nes (CRAT) , Paris,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Elefant","sequence":"additional","affiliation":[{"name":"AP-HP, Sorbonne Universit\u00e9, H\u00f4pital Piti\u00e9-Salp\u00eatri\u00e8re, D\u00e9partement de Sant\u00e9 Publique, Centre de R\u00e9f\u00e9rence sur les Agents T\u00e9ratog\u00e8nes (CRAT) , Paris,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B\u00e9n\u00e9dicte","family":"Coulm","sequence":"additional","affiliation":[{"name":"Sorbonne Universit\u00e9, INSERM, Institut Pierre Louis d\u2019Epid\u00e9miologie et de Sant\u00e9 Publique, \u00c9quipe PEPITES, AP-HP, H\u00f4pital Piti\u00e9-Salp\u00eatri\u00e8re, D\u00e9partement de Sant\u00e9 Publique, Centre de R\u00e9f\u00e9rence sur les Agents T\u00e9ratog\u00e8nes (CRAT) , Paris,","place":["France"]},{"name":"D\u00e9partement de Ma\u00efeutique, Sorbonne Universit\u00e9 , Paris,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8857-0910","authenticated-orcid":false,"given":"Benoit","family":"Marin","sequence":"additional","affiliation":[{"name":"Sorbonne Universit\u00e9, INSERM, Institut Pierre Louis d\u2019Epid\u00e9miologie et de Sant\u00e9 Publique, \u00c9quipe PEPITES, AP-HP, H\u00f4pital Piti\u00e9-Salp\u00eatri\u00e8re, D\u00e9partement de Sant\u00e9 Publique, Centre de R\u00e9f\u00e9rence sur les Agents T\u00e9ratog\u00e8nes (CRAT) , Paris,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,7,12]]},"reference":[{"key":"2025120216022786600_keaf387-B1","author":"Dictionnaire m\u00e9dical de l\u2019Acad\u00e9mie de M\u00e9decine"},{"key":"2025120216022786600_keaf387-B2","author":"Anon","year":"2013"},{"key":"2025120216022786600_keaf387-B3","author":"Anon"},{"key":"2025120216022786600_keaf387-B4","author":"Anon"},{"key":"2025120216022786600_keaf387-B5","author":"Anon"},{"key":"2025120216022786600_keaf387-B6","author":"Anon"},{"key":"2025120216022786600_keaf387-B7","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1136\/ard-2024-225851","article-title":"EULAR\/PReS recommendations for the diagnosis and management of Still\u2019s disease, comprising systemic juvenile idiopathic arthritis and adult-onset Still\u2019s disease","volume":"83","author":"Fautrel","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"2025120216022786600_keaf387-B8","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1080\/14767058.2019.1649392","article-title":"Maternal and fetal outcomes in pregnancies with long-term corticosteroid use","volume":"34","author":"Cai","year":"2021","journal-title":"J Matern Fetal Neonatal Med"},{"key":"2025120216022786600_keaf387-B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ard.2025.02.021","article-title":"Antirheumatic drugs in reproduction, pregnancy, and lactation: a systematic literature review informing the 2024 update of the EULAR recommendations","author":"Pluma","year":"2025","journal-title":"Ann Rheum Dis"},{"key":"2025120216022786600_keaf387-B10","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1016\/j.ard.2025.02.023","article-title":"EULAR recommendations for use of antirheumatic drugs in reproduction, pregnancy, and lactation: 2024 update","volume":"84","author":"R\u00fcegg","year":"2025","journal-title":"Ann Rheum Dis"},{"key":"2025120216022786600_keaf387-B11","doi-asserted-by":"crossref","first-page":"P28","DOI":"10.1186\/1546-0096-13-S1-P28","article-title":"IL-1 inhibition in Muckle\u2013Wells syndrome: withdrawal resulting in rapid deterioration of hearing loss","volume":"13","author":"Hansmann","year":"2015","journal-title":"Pediatr Rheumatol Online J"},{"key":"2025120216022786600_keaf387-B12","doi-asserted-by":"crossref","first-page":"66","DOI":"10.5152\/eurjrheum.2017.16075","article-title":"Anakinra use during pregnancy: report of a case with Familial Mediterranean fever and infertility","volume":"4","author":"Ilgen","year":"2017","journal-title":"Eur J Rheumatol"},{"key":"2025120216022786600_keaf387-B13","first-page":"1152","article-title":"Anakinra during pregnancy in a difficult to treat case of recurrent pericarditis","volume":"39","author":"Negro","year":"2023","journal-title":"Can J Cardiol"},{"key":"2025120216022786600_keaf387-B14","doi-asserted-by":"crossref","first-page":"e229","DOI":"10.1093\/rheumatology\/keac177","article-title":"Safety of canakinumab during pregnancy: seven new cases","volume":"61","author":"Weber","year":"2022","journal-title":"Rheumatology (Oxford)"},{"key":"2025120216022786600_keaf387-B15","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1007\/s10875-017-0389-3","article-title":"Placental transfer of canakinumab in a patient with Muckle\u2013Wells syndrome","volume":"37","author":"Egawa","year":"2017","journal-title":"J Clin Immunol"},{"key":"2025120216022786600_keaf387-B16","doi-asserted-by":"crossref","first-page":"key075.245","DOI":"10.1093\/rheumatology\/key075.245","article-title":"021\u2003Canakinumab use during pregnancy for the treatment of systemic onset juvenile idiopathic arthritis and refractory macrophage activation syndrome","volume":"57","author":"Gunn","year":"2018","journal-title":"Rheumatology"},{"key":"2025120216022786600_keaf387-B17","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1007\/s10067-022-06060-y","article-title":"Fetal exposure to canakinumab: a report of three pregnancies","volume":"41","author":"\u0130lgen","year":"2022","journal-title":"Clin Rheumatol"},{"key":"2025120216022786600_keaf387-B18","doi-asserted-by":"crossref","DOI":"10.1186\/1546-0096-11-S2-O13","article-title":"PReS-FINAL-2178: clinical and microarray follow-up of SJIA patients treated with anakinra over the past 10 years in a single institution","volume":"11","author":"Punaro","year":"2013","journal-title":"Pediatr Rheumatol"},{"key":"2025120216022786600_keaf387-B19","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.reprotox.2019.05.029","article-title":"#20 Anakinra use during pregnancy and lactation: a case report","volume":"88","author":"Duman","year":"2019","journal-title":"Reprod Toxicol"},{"key":"2025120216022786600_keaf387-B20","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1007\/s40744-021-00313-z","article-title":"Rituximab and canakinumab use during lactation: no detectable serum levels in breastfed infants","volume":"8","author":"Bosshard","year":"2021","journal-title":"Rheumatol Ther"},{"key":"2025120216022786600_keaf387-B21","doi-asserted-by":"crossref","first-page":"12","DOI":"10.3390\/biologics5020012","article-title":"Is canakinumab safe during pregnancy? New insights from three cases in Slovakia","volume":"5","author":"Slenker","year":"2025","journal-title":"Biologics"},{"key":"2025120216022786600_keaf387-B22","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1002\/art.38811","article-title":"Brief report: anakinra use during pregnancy in patients with cryopyrin-associated periodic syndromes","volume":"66","author":"Chang","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"2025120216022786600_keaf387-B23","doi-asserted-by":"crossref","first-page":"P124","DOI":"10.1186\/1546-0096-13-S1-P124","article-title":"How safe it is to treat pregnant FMF patients with Anakinra?","volume":"13","author":"Ozdogan","year":"2015","journal-title":"Pediatr Rheumatol"},{"key":"2025120216022786600_keaf387-B24","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1093\/rheumatology\/key093","article-title":"Five successful pregnancies with antenatal anakinra exposure","volume":"57","author":"Smith","year":"2018","journal-title":"Rheumatology (Oxford)"},{"key":"2025120216022786600_keaf387-B25","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s00393-017-0354-9","article-title":"IL-1-blockade mit anakinra in der schwangerschaft","volume":"77","author":"Venhoff","year":"2018","journal-title":"Z Rheumatol"},{"key":"2025120216022786600_keaf387-B26","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1093\/rheumatology\/kex305","article-title":"International multi-centre study of pregnancy outcomes with interleukin-1 inhibitors","volume":"56","author":"Youngstein","year":"2017","journal-title":"Rheumatology (Oxford)"},{"key":"2025120216022786600_keaf387-B27","doi-asserted-by":"crossref","first-page":"104583","DOI":"10.1016\/j.phrs.2019.104583","article-title":"Neonatal outcomes of children born to mothers on biological agents during pregnancy: state of the art and perspectives","volume":"152","author":"De Lorenzo","year":"2020","journal-title":"Pharmacol Res"},{"key":"2025120216022786600_keaf387-B28","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1097\/RHU.0000000000000873","article-title":"Effectiveness of canakinumab in colchicine- and anakinra-resistant or -intolerant adult familial Mediterranean fever patients: a single-center real-life study","volume":"26","author":"Babaoglu","year":"2020","journal-title":"J Clin Rheumatol"},{"key":"2025120216022786600_keaf387-B29","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.gofs.2024.04.004","article-title":"\u00c9tat des lieux sur les anti-IL-1 chez la femme enceinte","volume":"52","author":"Faure-Bardon","year":"2024","journal-title":"Gyn\u00e9col Obst\u00e9t Fertil S\u00e9nol"},{"key":"2025120216022786600_keaf387-B30","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/S0140-6736(07)61602-X","article-title":"The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"370","author":"von Elm","year":"2007","journal-title":"Lancet"},{"key":"2025120216022786600_keaf387-B31","author":"Anon","year":"2025"},{"key":"2025120216022786600_keaf387-B32","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/j.gofs.2024.05.005","article-title":"La nouvelle version du site internet du Centre de r\u00e9f\u00e9rence sur les agents t\u00e9ratog\u00e8nes et ses fonctionnalit\u00e9s optimis\u00e9es","volume":"52","author":"Coulm","year":"2024","journal-title":"Gyn\u00e9col Obst\u00e9t Fertil S\u00e9nol"},{"key":"2025120216022786600_keaf387-B33","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.therap.2024.03.004","article-title":"\u00c9valuation de la satisfaction des professionnels de sant\u00e9 utilisateurs du site internet du CRAT et lancement d\u2019une nouvelle version","volume":"79","author":"Marin","year":"2024","journal-title":"Therapies"},{"key":"2025120216022786600_keaf387-B34","doi-asserted-by":"crossref","first-page":"39","DOI":"10.2515\/therapie\/2014004","article-title":"[Centre de r\u00e9f\u00e9rence sur les agents t\u00e9ratog\u00e8nes (CRAT): a pioneer center]","volume":"69","author":"Elefant","year":"2014","journal-title":"Therapie"},{"key":"2025120216022786600_keaf387-B35","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.reprotox.2008.05.064","article-title":"Using observational cohort data for studying drug effects on pregnancy outcome\u2014methodological considerations","volume":"26","author":"Schaefer","year":"2008","journal-title":"Reprod Toxicol"},{"key":"2025120216022786600_keaf387-B36","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.ejogrb.2016.02.015","article-title":"Pregnancy loss: French clinical practice guidelines","volume":"201","author":"Huchon","year":"2016","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"2025120216022786600_keaf387-B37","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1002\/jpn3.12238","article-title":"Growth charts for use at birth and in the neonatal period: recommendations of the French Neonatal Society","volume":"79","author":"Guellec","year":"2024","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"2025120216022786600_keaf387-B38","author":"Anon"},{"key":"2025120216022786600_keaf387-B39","doi-asserted-by":"crossref","first-page":"e2314","DOI":"10.1002\/bdr2.2314","article-title":"Updated EUROCAT guidelines for classification of cases with congenital anomalies","volume":"116","author":"Bergman","year":"2024","journal-title":"Birth Defects Res"},{"key":"2025120216022786600_keaf387-B40","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1007\/978-90-481-9485-8_20","volume-title":"Rare diseases epidemiology","author":"Dolk","year":"2010"},{"key":"2025120216022786600_keaf387-B41","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.berh.2018.10.004","article-title":"Update on the epidemiology, risk factors and disease outcomes of Juvenile idiopathic arthritis","volume":"32","author":"Palman","year":"2018","journal-title":"Best Practice Res Clin Rheumatol"},{"key":"2025120216022786600_keaf387-B42","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/aji.12444","article-title":"Transplacental transfer of interleukin-1 receptor agonist and antagonist following maternal immune activation","volume":"75","author":"Girard","year":"2016","journal-title":"Am J Reprod Immunol"},{"key":"2025120216022786600_keaf387-B43","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1007\/s00345-015-1507-6","article-title":"Epidemiology of hypospadias in Europe: a registry-based study","volume":"33","author":"Bergman","year":"2015","journal-title":"World J Urol"},{"key":"2025120216022786600_keaf387-B44","author":"Anon"},{"key":"2025120216022786600_keaf387-B45","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.ajhg.2017.12.015","article-title":"Functional dysregulation of CDC42 causes diverse developmental phenotypes","volume":"102","author":"Martinelli","year":"2018","journal-title":"Am J Human Genetics"},{"key":"2025120216022786600_keaf387-B46","author":"Anon"},{"key":"2025120216022786600_keaf387-B47","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1016\/j.jgyn.2014.09.011","article-title":"\u00c9pid\u00e9miologie des pertes de grossesse","volume":"43","author":"Delabaere","year":"2014","journal-title":"J Gyn\u00e9col Obst\u00e9t Biol Reprod"},{"key":"2025120216022786600_keaf387-B48","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1111\/j.1600-0897.1996.tb00172.x","article-title":"Evolution of maternofetal transport of immunoglobulins during human pregnancy","volume":"36","author":"Malek","year":"1996","journal-title":"Am J Reprod Immunol"},{"key":"2025120216022786600_keaf387-B49","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1136\/annrheumdis-2015-208840","article-title":"The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation","volume":"75","author":"G\u00f6testam Skorpen","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"2025120216022786600_keaf387-B50","doi-asserted-by":"crossref","first-page":"225","DOI":"10.3390\/jcm11010225","article-title":"A systematic review of the safety of blocking the IL-1 system in human pregnancy","volume":"11","author":"Brien","year":"2021","journal-title":"J Clin Med"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/keaf387\/63735692\/keaf387.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/64\/12\/6106\/63735692\/keaf387.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/64\/12\/6106\/63735692\/keaf387.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T21:02:36Z","timestamp":1764709356000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/64\/12\/6106\/8198060"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,12]]},"references-count":50,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2025,7,12]]},"published-print":{"date-parts":[[2025,12,1]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keaf387","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,12]]},"published":{"date-parts":[[2025,7,12]]}}}